Cardiology

The Biology of CPVT and ARVC: Electrical vs. Structural Problems

At a Glance

CPVT is mainly an electrical problem caused by abnormal calcium handling, often involving RYR2, while ARVC/ACM damages heart muscle connections and can create scar tissue. Genetic testing, rhythm patterns, family history, and repeated imaging help distinguish them.

When doctors evaluate families for inherited arrhythmias, they are usually looking at one of two very different biological problems. While both can cause fast, dangerous heart rhythms, one is primarily a problem with the heart’s “batteries and wiring,” and the other is a problem with the heart’s “bricks and mortar” ^[1]^[2].

Understanding which biological mechanism is at work in your family helps explain why some people need strict exercise limits while others may require more frequent imaging of their heart muscle ^[3]^[4]. Note that these categories overlap, and triggers vary by syndrome.

CPVT: The Electrical “Calcium Leak”

Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) is a primary electrical disorder. In CPVT, the heart structure typically looks normal—the heart muscle is strong, and the “walls” of the heart appear fine on an ultrasound or MRI ^[1]^[5].

The problem lies deep within the heart cells in a system that handles calcium. Calcium is the signaling mineral that tells your heart muscle to contract ^[6].

The RYR2 “Gate”: Many cases of CPVT involve a mutation in the RYR2 gene. This gene provides instructions for a protein that acts like a gate, controlling when calcium is released to make the heart beat ^[7].
The Mechanism: In CPVT, this cellular control is unstable. When adrenaline rises—typically due to exercise or intense emotion—extra calcium leaks into the cell ^[8]^[9].
The Result: This extra calcium creates “hiccups” in the heart’s electrical system called delayed afterdepolarizations. These hiccups can trigger a chaotic, fast heart rhythm that usually appears when the heart is under stress ^[8]^[10].

ARVC/ACM: The Structural “Bricks and Mortar”

Arrhythmogenic Cardiomyopathy (ACM)—which includes the right-dominant form known as ARVC—is a structural disease of the heart muscle itself ^[2]^[11]. ACM can affect the right, left, or both ventricles.

The Desmosome “Glue”: The heart muscle cells are held together by proteins called desmosomes. Think of these as the “glue” or “velcro” between the cells of the heart wall ^[12].
The Mechanism: Mutations in genes like PKP2 or DSP weaken these connections. Over time, the constant mechanical stress of the heart beating can cause the cells to pull apart, become inflamed, or become damaged ^[2]^[13].
Fibrofatty Replacement: As the heart tries to heal this damage, it may replace the healthy muscle with fibrosis (scar tissue) and fat, though significant visible fat is not required for diagnosis ^[2]^[14].
The Result: This scar tissue and structural change create “roadblocks” that force the heart’s electrical signals to take detours, which can cause the signal to loop back on itself and create a fast, dangerous rhythm ^[15]^[12].

Distinguishing FVT from “Idiopathic” VT

You may hear doctors use the word idiopathic. This is a medical term for “arising from an unknown cause.” It is crucial to distinguish genetic inherited arrhythmias from these idiopathic conditions because the outlook and treatment differ.

Idiopathic Outflow-Tract VT

This is a common, usually benign form of VT where the extra beats come from one specific spot in the heart (the “outflow tract”) ^[16]^[17].

The Difference: In idiopathic VT, there is no identified genetic mutation and no progressive scarring. While it can feel scary, it often has an excellent long-term outlook. However, idiopathic RVOT VT still requires expert evaluation to exclude a concealed cardiomyopathy or channelopathy ^[16]^[18].

Idiopathic Ventricular Fibrillation (IVF)

This diagnosis is used when a patient has experienced a life-threatening rhythm (VF), but doctors cannot find any electrical or structural cause after extensive testing ^[19].

The Difference: IVF is a “diagnosis of exclusion.” Finding a genetic variant (like RYR2) in an IVF patient does not automatically establish CPVT or reclassify the diagnosis unless the clinical phenotype and family history strongly align ^[20]^[21]. A genetic variant supports risk but does not by itself prove a person has clinical disease.

Feature	CPVT (Electrical)	ARVC/ACM (Structural)	Idiopathic RVOT VT
Primary Genes	RYR2 ^[7]	PKP2, DSP ^[13]	None identified
Heart Structure	Typically Normal ^[1]	Scars/Fibrosis ^[2]	Normal ^[16]
Common Trigger	Typically Adrenaline ^[8]	Exercise / Random	Random
Basic Problem	Calcium handling ^[6]	Cell connections ^[12]	Single focus ^[17]

By identifying the specific biological cause, your medical team can move away from “wait and see” and toward a proactive plan that targets the exact mechanism of your heart’s rhythm ^[4].

Common questions in this guide

How are CPVT and ARVC different?

CPVT is mainly an electrical disorder: the heart usually looks structurally normal, but abnormal calcium handling can trigger dangerous rhythms during exercise or intense emotion. ARVC, which is part of arrhythmogenic cardiomyopathy, is a disease of the heart muscle that can cause injury, scar tissue, and changes in the ventricles. Both can be inherited and require specialist evaluation.

Why can exercise or stress trigger CPVT?

Exercise or strong emotion raises adrenaline. In some people with CPVT, gene-related problems with the RYR2 calcium-release gate allow extra calcium to leak inside heart cells, disrupting electrical signals and triggering a fast rhythm.

Can a normal echocardiogram rule out ARVC or arrhythmogenic cardiomyopathy?

No. Early arrhythmogenic cardiomyopathy may not be visible on one ultrasound, so doctors may use repeat ultrasound or MRI, heart rhythm patterns, genetic results, and family history to assess risk. Follow-up should be tailored by a cardiologist or cardiac electrophysiologist.

Does finding a gene variant prove that I have CPVT?

No. A genetic variant can support risk, but it does not by itself establish CPVT or reclassify idiopathic ventricular fibrillation. Doctors interpret the result alongside the rhythm pattern, symptoms, heart imaging, and family history.

What is idiopathic right ventricular outflow tract ventricular tachycardia?

It is ventricular tachycardia that starts in one area of the right ventricular outflow tract when no genetic cause or progressive scarring is identified. It often has an excellent long-term outlook, but expert evaluation is needed to rule out concealed arrhythmogenic cardiomyopathy or a primary electrical disorder.

Why does it matter whether ventricular tachycardia is electrical or structural?

The underlying mechanism helps determine follow-up and management. CPVT usually calls for attention to exercise and adrenaline triggers, while ARVC or ACM may require monitoring for structural changes with imaging. These conditions can overlap, so the care plan must be individualized.

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Familial ventricular tachycardia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Curated prompts to bring to your next appointment.

1.Based on my genetic test results, do I have a mutation in the RYR2 gene (electrical) or a desmosomal gene like PKP2 (structural)?
2.If my heart structure looks normal on an ultrasound today, how often should we repeat imaging like an MRI to check for future structural changes?
3.Is my ventricular tachycardia 'polymorphic' or 'monomorphic,' and how does that help confirm my specific diagnosis?
4.Could my diagnosis actually be idiopathic RVOT VT, and what steps are needed to exclude a concealed cardiomyopathy?
5.If I have CPVT, how does the 'calcium leak' in my heart cells explain why my symptoms usually happen during exercise or stress?

Key takeaways

CPVT usually has a structurally normal heart but can trigger dangerous ventricular rhythms during exercise or intense emotion because of abnormal calcium handling.
ARVC or ACM is a heart muscle disease in which weakened cell connections can lead to injury, scar tissue, and electrical instability.
RYR2 variants are associated with CPVT, whereas PKP2 and DSP variants are associated with ARVC or ACM, but a genetic result alone does not establish a clinical diagnosis.
Normal imaging today does not always exclude early structural disease, so follow-up imaging may be needed when clinical or family findings suggest risk.
Idiopathic right ventricular outflow tract ventricular tachycardia usually arises from one focus without identified genetic or progressive structural disease, but expert evaluation is needed to rule out concealed disease.

References (21)

1
CPVT: Arrhythmogenesis, Therapeutic Management, and Future Perspectives. A Brief Review of the Literature.
Baltogiannis GG, Lysitsas DN, di Giovanni G, et al.
Frontiers in cardiovascular medicine 2019; (6()):92 doi:10.3389/fcvm.2019.00092.
PMID: 31380394
2
Genetics of and pathogenic mechanisms in arrhythmogenic right ventricular cardiomyopathy.
Vimalanathan AK, Ehler E, Gehmlich K
Biophysical reviews 2018; (10(4)):973-982 doi:10.1007/s12551-018-0437-0.
PMID: 29995277
3
Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) Associated With Ryanodine Receptor (RyR2) Gene Mutations　- Long-Term Prognosis After Initiation of Medical Treatment.
Kawata H, Ohno S, Aiba T, et al.
Circulation journal : official journal of the Japanese Circulation Society 2016; (80(9)):1907-15 doi:10.1253/circj.CJ-16-0250.
PMID: 27452199
4
Management of Inherited Arrhythmia Syndromes: A HiRO Consensus Handbook on Process of Care.
Janzen ML, Davies B, Laksman ZWM, et al.
CJC open 2023; (5(4)):268-284 doi:10.1016/j.cjco.2023.02.006.
PMID: 37124966
5
Identification of two variants in AGRN and RPL3L genes in a patient with catecholaminergic polymorphic ventricular tachycardia suggesting new candidate disease genes and digenic inheritance.
Jaouadi H, Chabrak S, Lahbib S, et al.
Clinical case reports 2022; (10(2)):e05339 doi:10.1002/ccr3.5339.
PMID: 35341025
6
Structural and Functional Regulation of RyR2 in Cardiac Calcium Handling and Arrhythmogenesis.
Gao K, Wang W, Ling Y, et al.
Biomedicines 2026; (14(3)) doi:10.3390/biomedicines14030662.
PMID: 41898308
7
Extensive Ca2+ leak through K4750Q cardiac ryanodine receptors caused by cytosolic and luminal Ca2+ hypersensitivity.
Uehara A, Murayama T, Yasukochi M, et al.
The Journal of general physiology 2017; (149(2)):199-218 doi:10.1085/jgp.201611624.
PMID: 28082361
8
Multiphoton Imaging of Ca2+ Instability in Acute Myocardial Slices from a RyR2R2474S Murine Model of Catecholaminergic Polymorphic Ventricular Tachycardia.
Borile G, Zaglia T, E Lehnart S, Mongillo M
Journal of clinical medicine 2021; (10(13)) doi:10.3390/jcm10132821.
PMID: 34206855
9
Structural analyses of human ryanodine receptor type 2 channels reveal the mechanisms for sudden cardiac death and treatment.
Miotto MC, Weninger G, Dridi H, et al.
Science advances 2022; (8(29)):eabo1272 doi:10.1126/sciadv.abo1272.
PMID: 35857850
10
Clinical and molecular characterization of a cardiac ryanodine receptor founder mutation causing catecholaminergic polymorphic ventricular tachycardia.
Wangüemert F, Bosch Calero C, Pérez C, et al.
Heart rhythm 2015; (12(7)):1636-43.
PMID: 25814417
11
Two Novel Variants in Genes of Arrhythmogenic Right Ventricular Cardiomyopathy - a Case Report.
Gabartaitė D, Jančauskaitė D, Mikštienė V, et al.
Acta medica Lituanic 2021; (28(1)):127-135 doi:10.15388/Amed.2020.28.1.1.
PMID: 34393635
12
Arrhythmogenic cardiomyopathy: An in-depth look at molecular mechanisms and clinical correlates.
Costa S, Cerrone M, Saguner AM, et al.
Trends in cardiovascular medicine 2021; (31(7)):395-402 doi:10.1016/j.tcm.2020.07.006.
PMID: 32738304
13
International Evidence Based Reappraisal of Genes Associated With Arrhythmogenic Right Ventricular Cardiomyopathy Using the Clinical Genome Resource Framework.
James CA, Jongbloed JDH, Hershberger RE, et al.
Circulation. Genomic and precision medicine 2021; (14(3)):e003273 doi:10.1161/CIRCGEN.120.003273.
PMID: 33831308
14
Proposed diagnostic criteria for arrhythmogenic cardiomyopathy: European Task Force consensus report.
Corrado D, Anastasakis A, Basso C, et al.
International journal of cardiology 2024; (395()):131447 doi:10.1016/j.ijcard.2023.131447.
PMID: 37844667
15
Pathogenesis of Arrhythmogenic Cardiomyopathy.
Asimaki A, Kleber AG, Saffitz JE
The Canadian journal of cardiology 2015; (31(11)):1313-24.
PMID: 26199027
16
Idiopathic Polymorphic Ventricular Tachycardia: a "Benign Disease" with a Touch of Bad Luck?
Viskin S
Korean circulation journal 2017; (47(3)):299-306 doi:10.4070/kcj.2016.0303.
PMID: 28567077
17
Diagnostic electrophysiological study in a highly trained young woman with presyncopal symptoms during exercise: a case report.
de la Guía-Galipienso F, Sanchis-Gomar F, Quesada-Dorador A
Annals of translational medicine 2021; (9(2)):177 doi:10.21037/atm-20-3492.
PMID: 33569479
18
Comparison of patients with early-phase arrhythmogenic right ventricular cardiomyopathy and right ventricular outflow tract ventricular tachycardia.
Saberniak J, Leren IS, Haland TF, et al.
European heart journal. Cardiovascular Imaging 2017; (18(1)):62-69 doi:10.1093/ehjci/jew014.
PMID: 26903598
19
Latent Causes of Sudden Cardiac Arrest.
Krahn AD, Tfelt-Hansen J, Tadros R, et al.
JACC. Clinical electrophysiology 2022; (8(6)):806-821 doi:10.1016/j.jacep.2021.12.014.
PMID: 35738861
20
The genetics underlying idiopathic ventricular fibrillation: A special role for catecholaminergic polymorphic ventricular tachycardia?
Leinonen JT, Crotti L, Djupsjöbacka A, et al.
International journal of cardiology 2018; (250()):139-145 doi:10.1016/j.ijcard.2017.10.016.
PMID: 29032884
21
Identification of concealed cardiomyopathy using next-generation sequencing-based genetic testing in Korean patients initially diagnosed with idiopathic ventricular fibrillation.
Jeong JH, Kim YG, Oh SK, et al.
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2023; (25(11)) doi:10.1093/europace/euad313.
PMID: 37949661

This page explains how CPVT and ARVC or ACM differ for informational purposes only and does not constitute medical advice. Your cardiologist or cardiac electrophysiologist should interpret your genetic results, imaging, and rhythm findings.

Guide Contents